CASE REPORT

Cystic lymphangioma of the upper limb: Clinical case and literature review

1DAOUDA DIARRA, MD, 1YOUNES MEKOUAR, 1ABDOULFATAHI SALIHOU, 2BOUBACAR TRAORE, 1DALALE LAOUDIHY, 1KAMILIA CHBANI, 1SIHAM SALAM and 1LAHCEN EL OUZIDANE

1Department of Pediatric Radiology, CHU Ibn Rochd, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco
2Laboratory of Epidemiology, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco

Address correspondence to: Dr Daouda Diarra
E-mail: diarradaoud12@gmail.com

ABSTRACT:
We report an observation of a macro- and microcystic lymphatic malformation located in the right upper limb. This was a 5-year-old girl with no previous pathological history, followed since the age of 11 months for a congenital subcutaneous, painless and soft swelling of the right upper limb. Ultrasound of the soft tissue and magnetic resonance imaging (MRI) allowed the diagnosis of macro- and microcystic lymphatic malformation of the right upper limb. MRI plays an important role in the diagnosis and assessment of the tumor’s boundaries. Treatment can be difficult because of the location of the tumor and its extension into the surrounding tissue.

INTRODUCTION
Cystic lymphatic malformations, formerly called cystic lymphangiomas, are rare, hemodynamically inactive, benign, mature lymphatic malformations consisting of abnormal lymphatic vessels and cysts of various sizes and shapes.1-4 The most commonly used classification divides them into microcystic, macrocystic and mixed lesions depending on whether the volume of the cystic spaces is less than or greater than 2 cm3.5,6 Some authors prefer to classify them as capillary lymphangiomas, cavernous lymphangiomas and cystic hygromas.7

Macrocystic lymphatic malformations (MLMK), also known as cystic lymphangiomas or cystic hygromas, are a circumscribed variant of deep lymphangiomas that expand easily. They are usually located in the cervico-facial or axillary region and more rarely in the mediastinum or retroperitoneal region. Rarely, they are located in the limbs.8

On the other hand, microcystic lymphatic malformations may present as swellings under normal skin colour. They tend to progress over time and often induce deformities with functional repercussions depending on the topography. They may also be superficial and epidermal.9

We report an observation of cystic lymphangioma of the right upper limb.

CLINICAL PRESENTATION
She was a 5-year-old girl with no pathological history, from a non-consanguineous marriage, with good psychomotor development, followed since the age of 11 months for a congenital subcutaneous swelling of the right upper limb progressively increasing in volume.

The initial clinical examination revealed a right anterolateral thoracic subcutaneous swelling, right axilla extended to the right arm and forearm. On palpation, the swelling was painless, soft, and non-throbbing. The rest of the examination was unremarkable.

MRI showed a large formation containing multiple cystic pockets of varying size, some of which were macrocystic in the anterior chest wall, posterior and external arm wall.
and forearm, and others of which were microcystic in the axillary fossa and inner arm.

They have a pure fluid signal (T1 hypo signal and T2 hyper signal) with the septa showing an intermediate signal on T1, T2 and STIR sequences (Figure 1).

They are mostly subcutaneous with intramuscular extension to the pectoralis major and the posterior part of the arm with encroachment of the vascular pedicle in the axilla and humerus.

MRI was used to diagnose cystic lymphangioma of the right axillary soft tissue extending to the arm and upper third of the forearm, of macro- and microcystic type with vascular involvement and extension to the thorax.

**DISCUSSION**

Cystic lymphomas arise during embryonic development when the primary lymph sacs fail to fuse with the central venous system. They are round or lobulated and compressible masses.

Their incidence is approximately 1 per 12,000 births. They are present at birth in 30 to 50% of cases and are discovered in 90% of cases before the end of the second year of life. They rarely appear in adulthood.

The pathogenesis of MLMK is incompletely elucidated. However, advances have been made thanks to molecular biology. Indeed, many regulatory genes such as vascular endothelial growth factor of the surgical specimen showed a poorly limited lesion with cystic cavities; the histological study found a proliferation of lymphatic vessels without angiomatous component. The lateral and deep boundaries were unclear. The immediate postoperative course was simple with no significant complications.
receptors, VEGFR3 and VEGFR2, whose ligand is VEGF-C, have been implicated in the pathogenesis. These receptors are involved in the growth of lymphatic vessels in the skin without influencing the development of blood vessels. On the other hand, endothelial cells in cystic lymphangiomas have been found to secrete a significant amount of basic fibroblast growth factor (bFGF), which can be considered an inducer of angiogenesis. The level of thrombospondin-1 (an inhibitor of angiogenesis) secreted by the cells of lymphatic malformations is lowered in parallel. PMLKs will, therefore, be derived from these angiogenesis inducers.

MLMKs are in the neck in 75% of cases and in the axillae in 20% of cases, with the possibility of communication between these two locations via bridges passing under the clavicle. They are in the mediastinum, the retroperitoneum or the pelvic region in 5% of cases.

Involvement of the upper extremity, particularly the arm, is very rare. Indeed, a few rare cases of branchial localization (2/19 patients) and limb involvement (8/72 patients), including two in the upper extremity, have been found in patients with cystic lymphangiomas in the literature.

The number of lymphangiectatic vesicles, thickening, increased intracystic hemorrhage, which induces “natural sclerosis”. In contrast, microcystic components tend to progress over time, becoming thicker and more troublesome.

Macro cystic lymphatic malformations may regress after inflammatory flare-ups, especially with proximal infections, or after intracystic hemorrhage, which induces “natural sclerosis”. In contrast, microcystic components tend to progress over time, becoming thicker and more troublesome.

Microcysts may be superficial or epidermal and present as translucent or hemorrhagic millimetric vesicles, scattered or grouped in patches, called lymphangiectasias. They may be complicated by oozing (lymph) and bleeding when covered by verrucous hyperkeratosis, which can lead to long-term iron deficiency anaemia.

The appearance of the lymphangiectatic area may become purple in patches, called lymphangiectasias. They may be complicated by oozing ulcerations.

Ultrasound is of interest for positive and sometimes differential diagnosis. It shows multilocular cystic masses with septa of variable thickness. The contents are anechoic, hypoechoic or hyperechoic, depending on whether the lymphatic fluid is infected, haemorrhagic or hyperlipidic.

MRI highlights the characteristic aspect of hyposignal in T1 and hypersignal in T2. It also allows a better assessment of the extension of the tumour in different sections (sagittal, axial and coronal) and the involvement of adjacent structures that are not clinically suspicious, thus providing a valuable aid to surgery.

**Treatment**

Therapeutically, several means are available such as sclerotherapy, surgery, laser and radiotherapy. The indication depends essentially on the micro- or macrocystic type of the lymphatic malformation and its anatomical location.

Sclerotherapy is the first-line technique for disabling macrocystic lymphatic malformations.

It is less effective in microcystic lymphatic malformations. Depending on the availability of products, the experience of the practitioner, the macro- or microcystic character and the location of the malformation, different sclerosing agents can be used (hypertonic saline, lipiodol, bleomycin and boiling water). Ethibloc, the most commonly used sclerosing agent in France, appears to be successful in the treatment of MLMK. This agent polymerises rapidly on contact with the blood and appears to produce biodegradable emboli that are resorbed within 4 to 6 weeks after injection. It thus causes a gigantocellular reaction necessary for the walls of the cyst to collapse. This hardens and disappears in 2 to 6 months. The most frequent complications are febrile inflammatory reactions, inflammatory nodules and oozing ulcerations.

The results of this procedure are excellent or good in 60% of cases. Some complications, such as hemoglobinuria, are reported in up to 50% of patients after sclerotherapy with absolute ethanol. Overall, the risk of significant complications such as nerve damage, skin necrosis, pulmonary vasospasm, cardiac arrhythmia or cardiopulmonary collapse is in the order of 0 to 3%. Absolute ethanol is the sclerosing agent with the highest rate of serious complications.

**Surgery for cystic lymphatic malformations is a second-line technique**

Complete surgery limits the risk of recurrence, but it is rarely feasible. On the other hand, partial surgery may be indicated to reduce the volume of a large microcystic or mixed lymphatic malformation.

Removal of macrocystic lymphatic malformations can sometimes be difficult because of the anatomical location of the lesion, or its extension. The parotid region is the most difficult to approach. Thus, the complete removal of lymphangiomas sometimes requires several procedures.
Lasers and radiofrequencies are useful for superficial lymphangiectatic components of cystic lymphatic malformations but must be performed by an experienced operator. They are safe and effective in the short term but are suspensive. Very painful is that they are often performed under general anesthesia.

**Physiotherapy techniques**

Compression and manual lymph drainage have not been proven to be effective in cystic lymphatic malformations. They can be proposed and continued on a case-by-case basis, depending on the potential benefit for each patient.

**CONCLUSION**

Cystic lymphatic malformations can be symptomatic from the prenatal period or later in life, most often in childhood. The distinction between macrocystic, microcystic and mixed lymphatic malformations conditions the prognosis and the therapeutic approach.

This observation is original because of the unusual location and the macro- and microcystic type of the cystic lymphatic malformation. Moreover, it raises the therapeutic difficulties of these malformations. In first intention, macro-cystic lymphatic malformations are more likely to be treated by sclerotherapy, but surgical treatment should not be ruled out, especially in microcystic malformations.

**LEARNING POINTS**

- The distinction between macrocystic, microcystic and mixed lymphatic malformations conditions the prognosis and the therapeutic approach.

- Microcystic or mixed lymphatic malformations evolve over time with a tendency to progressive worsening.

- Ultrasound and MRI are the two imaging examinations indicated to confirm the diagnosis and to assess the extension of a cystic lymphatic malformation.

- The management of microcystic or mixed lymphatic malformations is more complex and is based on therapeutic strategies decided in multidisciplinary consultation, which may include sclerotherapy, physiotherapy, surgery, lasers, sirolimus, targeted therapy, successively or in combination, with windows of therapeutic abstention.

**REFERENCES**

1. Wierzbicka E, Herbreteau D, Robert M, Lorette G. Malformations lymphatiques kystiques. *Annales de Dermatologie et de Vénéréologie* 2006; 133: 597–601. https://doi.org/10.1016/S0151-9638(06)70973-5

2. Sjögren PP, Arnold RW, Skirko JR, Grimmer JF. Anatomic distribution of cervicofacial lymphatic malformations based on lymph node groups. *Int J Pediatr Otorhinolaryngol* 2017; 97: S0165–5876(17)30090-3: 72–75. https://doi.org/10.1016/j.ijporl.2017.02.030

3. Hogeling M, Adams S, Law J, Wargon O. Lymphatic malformations: clinical course and management in 64 cases. *Australas J Dermatol* 2011; 52: 186–90. https://doi.org/10.1111/j.1440-0960.2011.00777.x

4. Wiegand S, Eivazi B, Barth PJ, von Rautenfeld DB, Folz BJ, Mandic R, et al. Pathogenesis of lymphangiomas. *Vircحوا Arch* 2008; 453: 1–8. https://doi.org/10.1007/s00428-008-0611-z

5. Herbreteau D, Riche MC, Enjolras O, Lemarchand F, Laurian C, Brette MD, et al. Venous vascular malformations and their treatment with ethibloc. *J Mal Vasc* 1992; 17: 50–53.

6. Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. *Pediatrics* 2015; 136: e203–14. https://doi.org/10.1542/peds.2014-3673

7. Kennedy TL. Cystic hygroma-lymphangioma: a rare and still unclear entity. *Laryngoscope* 1989; 99: 1–10. https://doi.org/10.1288/00005537-198910001-00001

8. Pandit SK, Rattan KN, Budhiraja S, Solanki RS. Cystic lymphangioma with special reference to rare sites. *Indian J Pediatr* 2000; 67: 339–41. https://doi.org/10.1007/BF02820682

9. Gabeff R, Lorette G, Herbreteau D, le Touze A, Goga D, Maruani A. Malformations lymphatiques kystiques superficielles. *Annales de Dermatologie et de Vénéréologie* 2017; 144: 389–97. https://doi.org/10.1016/j.annder.2017.01.006

10. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development* 1996; 122: 3829–37. https://doi.org/10.1242/dev.122.12.3829

11. Eichmann A, Corbel C, Jaffredo T, Breant C, Joukov V, Kumar V, et al. Avian VEGF-C cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. *Development* 1998; 125: 743–52. https://doi.org/10.1242/dev.125.4.743
12. Maddalozzo J, Hughes CA, Huang L, Mu Y, Ludemann J, Crawford S. High angiogenic activity in cells isolated from cystic hygroma: role of bfgf. *Arch Otolaryngol Head Neck Surg* 1999; 125: 45–48. https://doi.org/10.1001/archotol.125.1.45

13. Carpenter CT, Pitcher JD, Davis BJ, Gomez R, Schofield TD, Youngberg RA. Cystic hygroma of the arm: a case report and review of the literature. *Skeletal Radiol* 1996; 25: 201–4. https://doi.org/10.1007/s002560050064

14. Wever DJ, Heeg M, Mooyaart EL. Cystic hygroma of the shoulder region. A case report. *Clin Orthop Relat Res* 1997: 215–18. https://doi.org/10.1097/00003086-199703000-00028

15. Sermon A, Gruwez JA, Lateur L, De Wever I. The importance of magnetic resonance imaging in the diagnosis and treatment of diffuse lymphangioma. *Acta Chir Belg* 1999; 99: 230–35. https://doi.org/10.1080/0015458.1999.12098485

16. Kennedy TL, Whitaker M, Pelleriti P, Wood WE. Cystic hygroma/lymphangioma: A rational approach to management. *Laryngoscope* 2001; 111: 1929–37. https://doi.org/10.1097/00005537-200111000-00011

17. Lerat J, Bisdorff-Bresson A, Borsic M, Chopinet C, Couloignier V, Fakhry N, et al. Recommandations de la SFORL (version courte) sur les malformations lymphatiques cervicales de l’adulte et de l’enfant : le diagnostic. *Annales Françaises d’Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale* 2019; 136: 110–14. https://doi.org/10.1016/j.aforl.2018.07.003

18. Sheth S, Nussbaum AR, Hutchins GM, Sanders RC. Cystic hygromas in children: sonographic-pathologic correlation. *Radiology* 1987; 162: 821–24. https://doi.org/10.1148/radiology.162.3.3544038

19. Rossi G, Iannicelli E, Almberger M, Innocenzi D, David V. Cystic lymphangioma of the upper extremity: US and MRI correlation (2004:11b). *Eur Radiol* 2005; 15: 400–402. https://doi.org/10.1007/s00330-004-2347-8

20. Emran MA, Dubois J, Laberge L, Al-Jazaeri A, Bütter A, Yazbeck S. Alcoholic solution of zein (ethibloc) sclerotherapy for treatment of lymphangiomas in children. *J Pediatr Surg* 2006; 41: 975–79. https://doi.org/10.1016/j.jpedsurg.2006.01.019

21. Heit JJ, Do HM, Prestigiagomo CJ, Delgado-Almandoz JA, English J, Gandhi CD, et al. Guidelines and parameters: percutaneous sclerotherapy for the treatment of head and neck venous and lymphatic malformations. *J Neurointerv Surg* 2017; 9: 611–17. https://doi.org/10.1136/neurintsurg-2015-012255